Telix Pharmaceuticals Completes Patient Enrollment in Phase Three Study of PSMA-PET Imaging Agents for Prostate Cancer Imaging

MT Newswires Live

Yesterday

Telix Pharmaceuticals (ASX:TLX) completed patient enrollment in the phase three BiPASS study of its prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging agents Gozellix and Illuccix for prostate cancer imaging in the pre-biopsy setting, with 350 patients enrolled in the US and Australia, according to a Wednesday Australian bourse filing.

The study seeks to evaluate whether the combination of magnetic resonance imaging and the imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography with Telix's proprietary gallium-68-PSMA-PET agents can improve diagnostic accuracy, reduce unnecessary biopsies, or improve targeting of biopsy compared with current standard practice.

The firm also aligned with the US Food and Drug Administration on a new drug application pathway for BiPASS.

Its shares rose nearly 1% in recent trading on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/2664867645"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664867645\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664867645?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 08:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664867645","market":"sg","top_or_hot":-1,"title":"Telix Pharmaceuticals Completes Patient Enrollment in Phase Three Study of PSMA-PET Imaging Agents for Prostate Cancer Imaging","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) completed patient enrollment in the phase three BiPASS study of its prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging agents Gozellix and Illuccix for prostate cancer imaging in the pre-biopsy setting, with 350 patients enrolled in the US and Australia, according to a Wednesday Australian bourse filing.</p><p>The study seeks to evaluate whether the combination of magnetic resonance imaging and the imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography with Telix's proprietary gallium-68-PSMA-PET agents can improve diagnostic accuracy, reduce unnecessary biopsies, or improve targeting of biopsy compared with current standard practice.</p><p>The firm also aligned with the US Food and Drug Administration on a new drug application pathway for BiPASS.</p><p>Its shares rose nearly 1% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix Pharmaceuticals Completes Patient Enrollment in Phase Three Study of PSMA-PET Imaging Agents for Prostate Cancer Imaging</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix Pharmaceuticals Completes Patient Enrollment in Phase Three Study of PSMA-PET Imaging Agents for Prostate Cancer Imaging\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-02 08:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) completed patient enrollment in the phase three BiPASS study of its prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging agents Gozellix and Illuccix for prostate cancer imaging in the pre-biopsy setting, with 350 patients enrolled in the US and Australia, according to a Wednesday Australian bourse filing.</p><p>The study seeks to evaluate whether the combination of magnetic resonance imaging and the imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography with Telix's proprietary gallium-68-PSMA-PET agents can improve diagnostic accuracy, reduce unnecessary biopsies, or improve targeting of biopsy compared with current standard practice.</p><p>The firm also aligned with the US Food and Drug Administration on a new drug application pathway for BiPASS.</p><p>Its shares rose nearly 1% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664867645","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664867645","pubTimestamp":1788310213,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Telix Pharmaceuticals (ASX:TLX) completed patient enrollment in the phase three BiPASS study of its prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging agents Gozellix a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK7067":"生物科技","TLX":"Telix Pharmaceuticals Ltd. (Uplisting)","TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"Telix Pharmaceuticals 完成用于前列腺癌成像的 PSMA-PET 显像剂三期研究的患者入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX":1.5,"TLX.AU":1},"content_text":"Telix Pharmaceuticals (ASX:TLX) completed patient enrollment in the phase three BiPASS study of its prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging agents Gozellix and Illuccix for prostate cancer imaging in the pre-biopsy setting, with 350 patients enrolled in the US and Australia, according to a Wednesday Australian bourse filing.The study seeks to evaluate whether the combination of magnetic resonance imaging and the imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography with Telix's proprietary gallium-68-PSMA-PET agents can improve diagnostic accuracy, reduce unnecessary biopsies, or improve targeting of biopsy compared with current standard practice.The firm also aligned with the US Food and Drug Administration on a new drug application pathway for BiPASS.Its shares rose nearly 1% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}